Parnell to Report Financial Results for Fiscal Year 2015 on February 24, 2016
18 Febrero 2016 - 7:00AM
Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully
integrated pharmaceutical company focused on developing,
manufacturing and commercializing innovative animal health
solutions, announced today that it will report financial results
for the full year ended December 31, 2015 on February 24, 2016 at
7:00 am ET.
Management will host a conference call on February 24, 2016 at
8:00 am ET to discuss fiscal year-end results. Investors and
analysts may access the conference call by dialing (877)
244-6184 FREE (U.S./Canada) or (920) 663-6271 (International)
and using the conference ID# 54549550.
A telephone replay will be available for one week following the
call by dialing (855) 859-2056 FREE (U.S./domestic) and (404)
537-3406 using the conference ID# 54549550.
A copy of the company's fiscal year-end financial results press
release will be furnished to the Securities and Exchange Commission
on a Form 6-K and posted on Parnell's website prior to the
call.
About Parnell
Parnell (NASDAQ:PARN) is a fully integrated pharmaceutical
company focused on developing, manufacturing and commercializing
innovative animal health solutions. Parnell currently markets
five products for companion animals and production animals in 14
countries and augments its pharmaceutical products with proprietary
software platforms - FETCHTM and mySYNCH®. These innovative
technology solutions are designed to enhance the quality of life
and/or performance of animals, while driving customers' operational
efficiency and profitability. Parnell distinguishes itself in the
industry by providing value-added solutions that position the
Company as a true partner to their customers.
For more information on the company and its products, please
visit www.parnell.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements and
information within the meaning of the U.S. Private Securities
Reform Act of 1995. Words such as "may," "anticipate," "estimate,"
"expects," "projects," "intends," "plans," "develops," "believes,"
and words and terms of similar substance used in connection with
any discussion of future operating or financial performance
identify forward-looking statements. Forward-looking statements
represent management's present judgment regarding future events and
are subject to a number of risk and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks include, but are not
limited to, risks and uncertainties regarding Parnell's research
and development activities, its ability to conduct clinical trials
of product candidates and the results of such trials, as well as
risks and uncertainties relating to litigation, government
regulation, economic conditions, markets, products, competition,
intellectual property, services and prices, key employees, future
capital needs, dependence on third parties, and other factors,
including those described in Parnell's Annual Report on Form 20-F
filed with the Securities and Exchange Commission, or SEC, on
September 15, 2014, along with its other reports filed with the
SEC. In light of these assumptions, risks, and uncertainties, the
results and events discussed in any forward-looking statements
contained in this press release might not occur. Investors are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date of this press release.
Parnell is under no obligation, and expressly disclaims any
obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
CONTACT:
For more information, contact:
Parnell Pharmaceuticals Holdings
Robert Joseph, 913-274-2100
robert.joseph@parnell.com
Brad McCarthy, 913-274-2100
brad.mccarthy@parnell.com
Parnell Pharmaceuticals (CE) (USOTC:PARNF)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Parnell Pharmaceuticals (CE) (USOTC:PARNF)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024